TY - JOUR AU - Genuino, Anne Julienne AU - Chaikledkaew, Usa AU - Guerrero, Anna Melissa AU - Reungwetwattana, Thanyanan AU - Thakkinstian, Ammarin PY - 2019 DA - 2019/11/21 TI - Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines JO - BMC Health Services Research SP - 874 VL - 19 IS - 1 AB - Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-positive early-stage breast cancer (EBC) in the adjuvant settings, and has been listed in the Philippine National Formulary (PNF) since 2008, but with no current evidence yet on its value for money, to date. Hence, despite several policy enablers, its accessibility remains to be limited in the Philippines. We performed an economic evaluation to assess the cost-effectiveness and budget impact of adjuvant trastuzumab therapy for HER2-positive EBC in the Philippines, using healthcare system and societal perspectives, in aid of guiding coverage decisions. SN - 1472-6963 UR - https://doi.org/10.1186/s12913-019-4715-8 DO - 10.1186/s12913-019-4715-8 ID - Genuino2019 ER -